Suppr超能文献

热休克蛋白 DNAJB8 调控肾肿瘤干细胞样细胞的肿瘤起始能力。

HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.

机构信息

Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.

出版信息

Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2.

Abstract

Cancer stem-like cells (CSC) are a small population of cancer cells with superior tumor initiating, self-renewal, and differentiation properties. In this study, we show that the cancer-testis antigen and HSP40 family member DNAJB8 contributes to the CSC phenotype in renal cell carcinoma (RCC). DNAJB8 overexpression increased the percentage of side population (SP) cells representing CSCs in RCC cells, enhancing their tumor-initiating ability. Conversely, attenuation of DNAJB8 decreased SP cells and reduced tumor-initiating ability. The utility of DNAJB8 as an immunologic target was established in DNA vaccination experiments. Compared with immunization with the tumor-associated antigen survivin, which was expressed in both CSCs and non-CSCs in RCC, immunization with Dnajb8 expression plasmids yielded stronger antitumor effects. Together, our findings suggest that DNAJB8 plays a role in CSC maintenance and that it offers a candidate for CSC-targeting immunotherapy in RCC.

摘要

癌症干细胞样细胞(CSC)是一小部分具有优越的肿瘤起始、自我更新和分化特性的癌细胞。在这项研究中,我们表明,癌症睾丸抗原和 HSP40 家族成员 DNAJB8 有助于肾细胞癌(RCC)中的 CSC 表型。DNAJB8 的过表达增加了侧群(SP)细胞的百分比,代表 RCC 细胞中的 CSCs,增强了它们的肿瘤起始能力。相反,DNAJB8 的衰减减少了 SP 细胞并降低了肿瘤起始能力。在 DNA 疫苗实验中确立了 DNAJB8 作为免疫靶标的实用性。与用在 RCC 中的 CSCs 和非 CSCs 中均表达的肿瘤相关抗原 survivin 免疫相比,用 Dnajb8 表达质粒免疫产生了更强的抗肿瘤作用。总之,我们的研究结果表明 DNAJB8 在 CSC 维持中发挥作用,并为 RCC 的 CSC 靶向免疫治疗提供了候选靶标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验